ORGANIZATION
JPMA’s Yoshida Urges Pro-Innovation Rules to Boost Japan’s Appeal amid MFN Fears
Japan could see further delays and losses in access to new medicines unless it bolsters pro-innovation pricing rules as the US presses ahead with its “most-favored-nation” (MFN) drug pricing policy, warns Yasunori Yoshida, the new senior managing director of the…
To read the full story
Related Article
- JPMA Names Ex-MHLW Pharma Official Yoshida as Senior Managing Director
September 12, 2025
ORGANIZATION
- FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
- Generic Use Rate Rises Further to 89.5% in July-September: JGA
January 5, 2026
- Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





